Literature DB >> 16210363

T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy.

Rui Han1, Terry J Smith.   

Abstract

Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease characterized by intense inflammation in the setting of volume expansion. At the heart of orbital susceptibility to Graves' disease appears to be the peculiar phenotype of orbital fibroblasts that, when activated by IL-1beta and other proinflammatory cytokines, produce excess prostaglandin E2 (PGE2) and hyaluronan. T helper type 1 (Th1) cytokines predominate early in TAO, whereas Th2 cytokines are more abundant later. It is currently unknown whether this transition might promote changes in tissue reactivity associated with disease progression. We report here that interferon-gamma and IL-4, representative of these respective classes of cytokines, attenuate IL-1beta-provoked PGE2 production. This down-regulation is mediated by blocking the induction of prostaglandin endoperoxide H synthase-2 (PGHS-2), the inflammatory cyclooxygenase. The mechanism involves blockade by IL-4 and interferon-gamma of the IL-1beta-dependent activation of PGHS-2 gene promoter activity. In addition, interferon gamma inhibits IL-1beta-provoked PGHS-2 mRNA stability. The actions of interferon-gamma and IL-4 are mediated through the Janus kinase 2/signal transducer and activator of transcription signaling pathway and could be abolished by treating with AG490, a specific inhibitor of Janus kinase 2. In contrast, the up-regulation of hyaluronan synthesis by IL-1beta is enhanced by either IL-4 or interferon-gamma. The latter two cytokines enhance the induction by IL-1beta of hyaluronan synthase-2 expression. These unexpected findings indicate that the Th1-->Th2 cytokine transition exerts equivalent influence on PGE2 and hyaluronan production as TAO progresses from early to late stage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210363     DOI: 10.1210/en.2005-1018

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  32 in total

Review 1.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

Review 2.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

3.  Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.

Authors:  Yuri Seo; Min Kyung Chae; Sol Ah Han; Eun Jig Lee; Joon H Lee; Jin Sook Yoon
Journal:  Inflamm Res       Date:  2017-03-31       Impact factor: 4.575

4.  Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.

Authors:  Naxin Guo; Collynn F Woeller; Steven E Feldon; Richard P Phipps
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

5.  Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse.

Authors:  Paul L Bollyky; Stephen P Evanko; Rebecca P Wu; Susan Potter-Perigo; S Alice Long; Brian Kinsella; Helena Reijonen; Kelly Guebtner; Brandon Teng; Christina K Chan; Kathy R Braun; John A Gebe; Gerald T Nepom; Thomas N Wight
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 6.  Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.

Authors:  Terry J Smith; Laszlo Hegedüs; Raymond S Douglas
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

7.  Novel anti-adipogenic activity produced by human fibroblasts.

Authors:  Geniece M Lehmann; Collynn F Woeller; Stephen J Pollock; Charles W O'Loughlin; Shikha Gupta; Steven E Feldon; Richard P Phipps
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-16       Impact factor: 4.249

8.  Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Authors:  Xiaomei Liu; Hui Guo; Juan Liu; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

Review 9.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

Review 10.  Regulation of T helper cell subsets by cyclooxygenases and their metabolites.

Authors:  Hong Li; Matthew L Edin; Artiom Gruzdev; Jennifer Cheng; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-11-28       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.